Last reviewed · How we verify

Ochsner Health System — Portfolio Competitive Intelligence Brief

Ochsner Health System pipeline: 4 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
intravenous NAC intravenous NAC marketed
Ambrisentan Pill Ambrisentan Pill marketed
Slow Infusion of Rubidium-82 Slow Infusion of Rubidium-82 marketed Positron emission tomography (PET) imaging agent Na+/K+-ATPase pump (potassium analog) Cardiovascular
Furosemide plus Chlorothiazide Furosemide plus Chlorothiazide marketed Loop diuretic + thiazide diuretic combination Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre hospitalier de l'Université de Montréal (CHUM) · 1 shared drug class
  2. Eastern Health, Canada · 1 shared drug class
  3. National Heart, Lung, and Blood Institute (NHLBI) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ochsner Health System:

Cite this brief

Drug Landscape (2026). Ochsner Health System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ochsner-health-system. Accessed 2026-05-16.

Related